Uptrend on the daily chart: above its 50- and 200-day averages · 50-day below the 200-day · SuperTrend up since Oct 1 · above the Ichimoku cloud · RSI 63 · MACD above its signal
| 9.13 | 52-week high | +46.08% |
| 6.51 | Previous week high | +4.08% |
| 6.50 | R3 (classic) | +4.00% |
| 6.44 | R2 (classic) | +3.04% |
| 6.38 | Previous day high | +2.08% |
| 6.35 | R1 (classic) | +1.52% |
| 6.29 | Pivot | +0.56% |
| 6.25 | Price now | |
| 6.22 | Previous day low | −0.40% |
| 6.19 | S1 (classic) | −0.96% |
| 6.13 | S2 (classic) | −1.92% |
| 6.05 | Previous week low | −3.20% |
| 6.03 | S3 (classic) | −3.44% |
| 5.54 | Previous month high | −11.36% |
| 5.05 | Previous month low | −19.28% |
| 5.05 | 52-week low | −19.28% |
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $3.1M | 0.00% | 476.70K | — | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a INGN trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Aug 31, 2026 | Smith Kevin P.General Counsel | — | 18.1K | — |
| Aug 31, 2026 | Smith Kevin Raymond MerrillChief Executive Officer | Stock Award(Grant) at price 5.33 per share. | 1.5K | $8.00K |
| Aug 31, 2026 | Smith Kevin P.General Counsel | Stock Award(Grant) at price 5.33 per share. | 1.5K | $8.00K |
| Aug 31, 2026 | Wright Mary EOfficer | Stock Award(Grant) at price 5.33 per share. | 1.5K | $8.00K |
| Jun 30, 2026 | Yi Boyer Jennifer MOfficer | Sale at price 6.60 per share. | 10.9K | $72.15K |
| Jun 4, 2026 | Mora Elizabeth ADirector | Stock Award(Grant) at price 0.00 per share. | 28.1K | — |
| Jun 4, 2026 | Rider Heather D.Director | Stock Award(Grant) at price 0.00 per share. | 28.1K | — |
| Jun 4, 2026 | King Kevin MDirector | Stock Award(Grant) at price 0.00 per share. | 28.1K | — |
| Jun 4, 2026 | Boehnlein Glenn SDirector | Stock Award(Grant) at price 0.00 per share. | 28.1K | — |
| Jun 4, 2026 | Ladone Mary KayDirector | Stock Award(Grant) at price 0.00 per share. | 28.1K | — |
| Jun 4, 2026 | Jamali VafaDirector | Stock Award(Grant) at price 0.00 per share. | 28.1K | — |
| Jun 4, 2026 | Sahney Mira KirtiDirector | Stock Award(Grant) at price 0.00 per share. | 28.1K | — |
| May 28, 2026 | Yi Boyer Jennifer MOfficer | Sale at price 6.53 per share. | 10.8K | $70.31K |
| Feb 26, 2026 | Bourque Michael JChief Financial Officer | — | 42K | — |
| Feb 26, 2026 | Ramade GregoireOfficer | — | 13K | — |
| Feb 26, 2026 | Smith Kevin Raymond MerrillChief Executive Officer | — | 58.3K | — |
| Feb 26, 2026 | Smith Kevin P.General Counsel | — | 14K | — |
| Feb 26, 2026 | Yi Boyer Jennifer MOfficer | — | 25K | — |
| Feb 26, 2026 | Wright Mary EOfficer | — | 7.5K | — |
| Feb 26, 2026 | Bourque Michael JChief Financial Officer | Stock Award(Grant) at price 0.00 - 6.10 per share. | 29.7K | $5.33K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -12.2 | 3.4 | 1.3 | 15.0 | -8.7 | -0.6 | 0.0 | -16.7 | -1.9 | 18.6 | −7.0% | ||
| 2025 | 27.5 | -28.7 | -14.4 | 0.0 | -9.9 | 9.4 | -10.2 | 26.6 | 2.3 | 0.9 | -14.1 | -5.1 | −26.7% |
| 2024 | 29.6 | -6.5 | 21.4 | -15.7 | 22.1 | -2.0 | 13.8 | 32.6 | -20.9 | -10.0 | 11.2 | -5.6 | +67.0% |
| 2023 | 18.4 | -32.8 | -20.4 | 6.7 | -20.9 | 9.7 | -29.3 | -24.0 | -15.9 | -14.4 | 30.2 | -5.7 | −72.1% |
| 2022 | -12.6 | 17.4 | -7.1 | -22.0 | 1.6 | -5.8 | 15.1 | 2.9 | -15.2 | -6.7 | -1.5 | -11.7 | −42.0% |
| 2021 | 9.5 | 7.3 | 0.1 | 24.5 | -5.5 | 5.4 | 22.4 | -25.8 | -27.2 | -8.0 | -23.0 | 11.3 | −23.9% |
| 2020 | -35.2 | 3.4 | 12.8 | -3.2 | -24.0 | -6.5 | -13.6 | -1.5 | -4.1 | 0.7 | 20.1 | 27.4 | −34.6% |
| 2019 | 21.8 | -28.9 | -11.3 | -8.5 | -26.2 | 3.6 | -7.9 | -24.6 | 3.3 | 13.6 | 35.2 | -7.2 | −45.0% |
| 2018 | 2.3 | -0.8 | 1.7 | 14.4 | 30.0 | 2.0 | 6.9 | 33.0 | -7.8 | -22.3 | -22.3 | -15.7 | +4.3% |
| 2017 | -4.2 | 6.6 | 13.0 | 6.9 | 6.9 | 7.6 | -1.1 | 1.5 | -0.7 | 4.0 | 30.1 | -7.5 | +77.3% |
| 2016 | -17.1 | 2.8 | 31.6 | 8.6 | -2.3 | 5.0 | 7.2 | 8.0 | 3.2 | -10.4 | 20.0 | 4.3 | +67.5% |
| 2015 | -2.5 | 8.7 | -3.8 | 14.8 | 1.7 | 19.3 | -0.3 | 10.9 | -1.5 | -12.0 | -10.5 | 4.8 | +27.8% |
| 2014 | -5.7 | -14.5 | 18.9 | 34.4 | -11.3 | 3.2 | -0.2 | 14.6 | 2.9 | 29.1 | +79.2% |
TimeframesUp on the daily, down on the hourly and monthly, mixed on the weekly.
under a falling 21 EMA, 21 under 50
over a rising 21 EMA, 21 over 50
bouncing over the 21 EMA
under a falling 21 EMA, 21 under 50
Buy / hold / sell counts
Inogen, Inc., a medical technology company, develops, manufactures, and markets respiratory health products in the United States and internationally. The company offers portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. It provides Inogen One and Inogen Rove, an ambulatory solution for long-term oxygen therapy; Rove 4, a portable oxygen concentrator; Rove 6 concentrator; Inogen Voxi 5, a stationary oxygen concentrator; Aurora for continuous positive airway pressure; CPAP masks; Simeox for airway clearance treatment; and related accessories. It also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Beverly, Massachusetts.